Medicare AdvantageCoverageMedium impact

Coverage of Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) for Measles Post-Exposure Prophylaxis in Medicare Advantage Members

Q: Who is affected by this change?

This affects Independence Blue Cross Allergy & Immunology, Infectious Disease, Pediatrics, Internal Medicine, Family Medicine providers on Medicare Advantage plans.

Independence Blue Cross·Allergy & Immunology, Infectious Disease, Pediatrics +2 more·News & Announcements

Effective date

Not stated

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new policy has been announced regarding coverage of Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) for measles post-exposure prophylaxis in Medicare Advantage members. This policy establishes coverage criteria for these treatments when used specifically for measles exposure prevention.

Action Required

Action needed

Review the full policy details at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing guidelines for IVIG and SCIG when used for measles post-exposure prophylaxis. Update billing procedures once complete policy details are available.

Related policy hubs

Independence Blue Cross policies Allergy & Immunology Infectious Disease Pediatrics Internal Medicine Family Medicine